About Us

Nick-La-Thangue-78920

Our main focus is:

"Argonaut Therapeutics is a precision medicine company developing transformative epigenetic therapeutics to treat cancer. "

Nicholas La Thangue

Overview

Argonaut Therapeutics is a precision therapeutics company that was established to develop epigenetically-acting drugs which target abnormal arginine methylation in cancer. The company was founded on pioneering research from the University of Oxford, UK. Argonaut strives to develop a new class of precision cancer medicines which target the enzymes responsible for abnormal arginine methylation in cancer.

Our Team

Nick-La-Thangue-78920

Nicholas La Thangue

Chief Executive Officer

Nick has extensive experience of cancer drug development and has founded several companies, including Prolifix and Celleron Therapeutics and more recently Oxford Cancer Biomarkers. He has extensive commercial experience in the biotechnology and pharmaceutical sectors.
He is a fellow of the Royal Society of Edinburgh, a member of the European Molecular Biology Organisation (EMBO), A Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick is Chair of Cancer Biology at the University of Oxford.

Shonagh Munro

Research Director

Shonagh has extensive cancer biology research experience having been previously employed in the Department of Oncology at the University of Oxford for more than 13 years. Her research, which primarily focused upon understanding the mechanisms that control cancer cell growth and death, resulted in numerous publications in peer-reviewed journals. She has a degree in Biomedical Sciences and a PhD in Molecular Biology.

We are recruiting!

Board of Directors

Simon Kerry

Simon Kerry

Chairman and Director

Simon has two decades’ experience of creating and developing innovative life science companies. He is currently an Operating Partner at Advent Life Sciences and works closely with a number of portfolio companies. He was CEO of Karus until 2017, having joined them in 2006. Before Karus, he was Director of Business Development at Ablynx NV (Ghent, Belgium), where he secured a number of research, development and licensing agreements with major pharmaceutical companies including Wyeth (now Pfizer) and Novartis. Prior to Ablynx, Simon was Director of Business Development at Active Biotech AB (Lund, Sweden), where he spun-out the molecular evolution company, Isogenica Ltd (Cambridge, UK), later joining the spin-out as Vice President of Business Development. Simon has a degree in Medicinal Chemistry, a Life Science PhD and an executive MBA from Loughborough University Business School.

Andrew Mclean - Headshot

Andrew McLean

Investor Director

Is currently Life Sciences Head at Oxford Science and Innovation. Andy joined OSI from McKinsey & Co. At McKinsey he was deeply embedded in both the private equity and pharmaceuticals practices. He is a physician with training in orthopaedic surgery who also completed a degree in philosophy, politics and economics at Christ Church, Oxford. He cut his investing teeth on the trading floor at Goldman Sachs.

Nick-La-Thangue-78920

Nicholas La Thangue

Chief Executive Officer

Nick has extensive experience of cancer drug development and has founded several companies, including Prolifix and Celleron Therapeutics and more recently Oxford Cancer Biomarkers. He has extensive commercial experience in the biotechnology and pharmaceutical sectors.
He is a fellow of the Royal Society of Edinburgh, a member of the European Molecular Biology Organisation (EMBO), A Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick is Chair of Cancer Biology at the University of Oxford.

Chairman Lee

Kyung Ha Lee

Director

Mr. Lee is currently Chairman of JW group. He joined JW Pharmaceutical in 1986 and served as the head of Marketing Headquarter, President of C&C Research Laboratories and CEO of JW Pharmaceutical and JW Holdings. He was also the vice-board president of Korea Pharmaceutical Manufacturers Association (KPMA). He graduated from the pharmacy school of Sung Kyun Kwan University and received his MBA degree from Drake University. He received the Korea Drug Research Association Award for New Medicine Development in 2002.

BK.Lee

Mr Bungkwn Lee

Investor Director Argonaut Therapeutics Limited

Formerly Bond Dealer in Bank of New York Seoul Branch. Formerly CEO of  Sudokwon Enviroment Company. Now CEO of Muhan Coproration.,Ltd and Professional Investor.

Investors

small logo-3
Read more
small logo-2
Read more
small logo-1
Read more